major pathogens (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and Staphylococcus aureus) exceeded 50% of the dose interval were amoxycillin/clavulanate (500/125 mg) and ceftriaxone. For macrolides, T > MIC is relevant for erythromycin and clarithromycin, but not azithromycin, for which AUC is the parameter most closely linked to outcome. Erythromycin, clarithromycin and azithromycin showed efficacy against M. catarrhalis only at MICV Quinolones (ciprofloxacin and ofloxacin), for which AUC is also the relevant phannacodynamic parameter, had the greatest activity against H. influenzae and M. catarrhalis at MIG», but were less effective against S. pneumoniae and 5. aureus. Susceptibility data such as those provided by the Alexander Project can aid clinicians in choosing appropriate treatment for LRTI based on pharmacodynamic principles.
Introduction
A considerable body of work has emerged in the last 15 years linking different measures of pharmacological exposure to an antimicrobial agent to the outcome observed in the setting of a serious infection. These data have been developed in vivo in animal model systems, and in patients, and allow rational extrapolation from in-vitro data to expected clinical utility.
There are two factors which influence potential utility of a drug in a specific clinical situation. The first is some measure of potency of the antibiotic for the pathogen in question (MIC, MBC, etc.) . The second is whichever relationship between the concentration-time profile and potency of the antibiotic is linked most robustly to clinical outcome (Time above MIC or MBC [T > MIC or T > MBC]; Peak/MIC or MBC; AUC/MIC or AUC/MBC).
The second factor has been documented extensively for /?-lactam drugs. Clearly, on the basis of in-vitro data, animal model system data and, most importantly, clinical trial data, the time the free antibiotic concentration remains above the MIC (MBC) is most clearly linked to outcome (Drusano, 1988) . /?-Lactam kill-rates are relatively concentration independent. That is, in the in-vitro situation, increasing the concentration of the /Mactam has little effect on the kill rate observed. Indeed, for most strains, there is only a mild increase in kill rate as the concentration increases from the MIC (or MBC) to four times the MIC (or MBC). After this, there is little further increase in the rate of bacterial killing with increasing concentration.
These data employing /?-lactam agents are in stark contrast to data developed with other classes of anti-infective drugs. Drugs such as aminoglycosides and fluoroquinolones have a highly concentration-dependent kill rate. Increasing exposure concentrations results in major increases in kill rate over a wide range. For these agents, the total number of organisms killed is merely a path integral of concentrationdependent kill rate times. It is straightforward, then, that the area under the concentration-time curve (AUC), itself an integral of the concentration over time, is the variable most directly linked to organism kill and ultimate outcome for agents which are concentration-dependent in kill rate.
What other data are there that support the suggestion that time above MIC is the most important pharmacological measure linked to successful therapy? Zinner et al. (1988) studied cefoperazone in an in-vitro hollow fibre system and these data clearly indicated that the time that the drug concentration exceeded the MIC for the pathogen was the measure most closely linked to outcome.
Convincing data indicating that T > MIC was important were generated by Gerber et al. (1983) in an animal model. In this system, mice were rendered neutropenic with cyclophosphamide, allowing the underlying relationship between drug exposure and response to be studied more easily. In the first of a series of publications from this group, ticarcillin was the antibiotic employed. Animals were infected with Pseudomonas aeruginosa in the thigh, and ticarcillin was given as a large dose every 3 h and compared with one-third of the same dose administered every hour. The difference in outcome is displayed in Figure 1 . Clearly, the smaller dose, given more frequently so maximizing the time that plasma concentrations exceed the MIC for the P. aeruginosa, was significantly more effective in controlling the infection at the primary site.
Later, this group examined another way of discerning the pharmacological variable most closely linked to outcome (Leggett et al., 1989) . Small numbers of animals were examined over a large number of doses and schedules. The outcomes were examined explicitly using a sigmoid-dose-effect model. Once again, T > MIC was the variable most closely linked to outcome (Table I) .
Other groups, such as those of Bakker-Woudenberg (Roosendaal et al., 1986 ) have also shown that, for drugs such as ceftazidime, T > MIC is the important dynamically-linked variable in both neutropenic and normal animals infected with Klebsiella pneumoniae (Table II) . In this instance, use of continuous infusion resulted in a three-to 15-fold decrease in the total dose of antibiotic necessary to completely protect a cohort of animals compared with intermittent administration of the drug.
Most recently, Craig's group (Craig, W., personal communication) provided a most interesting insight into this problem. While previous animal model data indicate that T > MIC is important for /Mactams, the question still arises if there is a certain minimum amount of the dosing interval during which the concentration needs to be above the MIC. Craig's group addressed this problem by determining the static point, i.e. the percentage of the dosing interval needing to be covered to reach the point where a bacterial inoculum in an animal thigh neither multiplied nor was killed. Multiple , 1983) dosing intervals were evaluated. Interestingly, for penicillins and cephalosporins, a constant 50-60% of the dosing interval needed to be covered by drug in order to achieve bacterial stasis. This provides an insight into the minimal expectation which we should have of a /?-lactam antibiotic for a specific pathogen. Thus, for empirical use, a /Mactam with relatively low protein binding should achieve concentrations in excess of the MIG» of the pathogen for which the antibiotic is to be employed for a minimum of 50% of any proposed dosing interval. In patients, there are also data that support the concept of T > MIC being linked to outcome. The data developed by several groups that a serum inhibitory or bactericidal titre of 1:8 or 1:16 at peak antibiotic concentrations (1 h after the end of an intravenous infusion of 30 min-1 h duration) is linked to outcome supports the concept that T > MIC is truly linked to outcome (Klastersky et al., 1974; Platt et al., 1981; Sculier& Klastersky, 1984) . One doubling dilution in this assay occurs in vivo over a single terminal elimination half life. Consequently, titres of 1:8 or 1:16 indicate that Table I . Stepwise multilinear regression analysis of drug efficacy on three predictors (time levels exceeded the MIC, T > MIC; log l0 AUC above the MIC, AUC > MIC; and logio peak level) (cf. Leggett et al., 1989) Drug (mg/kg), MIC (mg/L), infection site (no. of mice)
Cefazolin (9.375-1200), 2.4 thigh (48) lung ( thigh (36) lung (72) Ceftazidime (0.293-75), 0.15 thigh (52) lung (116) Gentamicin (1.5-24), 0.27
thigh (32) ql-6h' q6-12h' lung (80) ql-6h' q6-12h" Netilmicin (0.1875-24), 0.12 thigh (42)
Parameter ( 'A larger coefficient indicates a greater change in logio cfu for a given unit of change in the parameter. *Only parameter selected by stepwise regression (P < 0.05). 'Best univariate parameter selected by stepwise regression. 'Analysis of regimens with 1-6 h or 6-12 h dosing intervals only; q, every.
three to four terminal half lives can elapse and there will still be sufficient antibiotic available to inhibit or kill the microorganism. This is 1 h after the end of the infusion (a time span of 1.5-2.0 h). For an antibiotic with a half life of 1 h, this implies a minimum time of 4.5 h of coverage and a maximum time of 6.0 h of coverage. For antibiotic with a 2 h half life, these figures are 7.5-10 h. As dosing intervals for these studies were between 4 and 8 h, it is not surprising these titres were significantly associated with a good clinical outcome. One of the earliest clinical trials which specifically examined this issue was performed by Bodey, Ketchel & Rodriguez (1979) . A continuous infusion of cefamandole was compared with intermittently administered cefamandole. Both groups had intermittently administered carbenicillin as part of the regimen. The study examined febrile, Table II . Efficacy of ceftazidime treatment schedules* in normal and leucopenic* rats (cf. Roosendaal et al., 1986) Normal rats (n = 10) intermittent administration continuous administration 2.8 ± 0.4 5.2 ± 1.9 9.3 ±3.5
"To groups of ten rats each ceftazidime was administered either as intermittent bolus injections at 6 h intervals or as a continuous infusion (infusion rate, 0.113 ml/h) over a period of 4 days. Treatment was started 5h after inoculation of the left lung with 8 x 10* cfu of K. pneumoniae. The PD»s (mg/kg/day) for intermittent administration and continuous administration for normal rats were 0.35 and 0.36, respectively (99.9% confidence limits, 0.19-0.67 and 0.21-0.61, respectively); the corresponding values for leucopenic rats were 24.37 and 1.52 (16.07-36.97 and 1.00-2.31). teftazidime was administered intraperitoneally in two doses of 90 and 60 mg/kg at 5 days and 1 day before bacterial inoculation, respectively.
'Mean ± S.D., based on the time of bacterial inoculation (day 0). Table III demonstrates that the outcomes always tended to be better with continuous infusion and were significantly better in two of the patient groups. Warren et al. (1983) examined cefoperazone as part of a randomized evaluation in septic patients. Ten patients had documented single organism, Gram-negative bacillus bacteraemia. Nine of these patients had a correct prediction of success or failure made on the basis of the expected time above the MIC. Perhaps the most convincing clinical evidence comes from the study by Schentag et al. (1984) . These investigators examined the cephalosporin, cefmenoxime, in patients with Gram-negative pneumonia. They documented the time that plasma concentrations exceeded the MIC of the pathogen (T > MIC) and also measured the time to eradication of the pathogen from the lower tracheobronchial tree. There was an excellent inverse relationship between T > MIC and time to bacterial eradication ( Figure 2) .
Consequently, there are multiple lines of evidence (in-vitro, animal model and clinical), suggesting that T > MIC is the pharmacological variable most closely linked to bacterial killing and a good clinical outcome for the /J-lactam class of agents. It is also likely that only the free drug is microbiologically active (Drusano, 1988) and, consequently, a conservative evaluation of this factor (T > MIC) would employ the free drug in this calculation.
The other factor which affects our judgement regarding the potential utility of a /3-lactam antibiotic is the MIC for the organism(s) against which the drug is to be used empirically. The reason for examining the distribution of the MICs is quite straightforward. While T > MIC is the variable which is truly linked to outcome, most of the change in this variable is a consequence of changes in the MIC. For example, a two-fold range of dose may be available for a licensed agent (e.g. 250 or 500 mg). There may be a 50% coefficient of variation in the clearance of the drug in the population of patients in which use is intended; this will produce (approximately) a six-fold range of exposure (the pure pharmacological variable). However, there is often a 64-or even a 128-fold range in the MICs for the pathogens for which the drug is intended for empirical use. Consequently, there is a much greater degree of variability in the microbiological end of the equation relative to the pharmacological end. Therefore, the determination of the distribution of MICs of a large number of drugs for respiratory pathogens in different areas of the world is a critically important piece of information if these agents (and in particular, the /Mactam drugs) are to be placed in proper perspective.
It is one of the aims of the Alexander Project to generate a database with a substantial number of isolates derived from Western Europe and the USA and to determine their susceptibilities to a panel of antimicrobial agents employing a standardized methodology. This database is one which is being developed, allowing trends in susceptibility for multiple antibiotics to be recognised, by site, by time and always with the aim of placing the potential utility of these commonly used agents in proper perspective. This can be done most straightforwardly and rationally for the /?-lactams by examining the time that antibiotic concentrations exceed the MIC90 of these clinically important pathogens; the most conservative estimate is to use the free drug concentration in any analysis.
How does one assess the other classes of antibiotics under investigation in the Alexander Project, and in particular macrolides and fluoroquinolones, which are widely used in the participating countries?
Fluoroquinolones exhibit concentration-dependent bactericidal activity, and therapeutic outcome should be linked to AUC. This was clearly demonstrated by Leggett et al. (1991) for ciprofloxacin in murine pneumonitis and thigh infection models.
The situation for macrolides is confused, partly because erythromycin is generally considered as a bacteriostatic agent, but bactericidal against streptococci. Clarithromycin and azithromyan are considered more bactericidal than erythromycin (Piscitelli, Danziger & Rodvold, 1992) . In addition, macrolides are concentrated by macrophages and azithromycin is characterised by slow efflux from cells (ion-trapping). Gerber (1990) noted that, for a range of pathogens in the neutropenic mouse thigh 0 2 4 6 8 10 Cefmenaxime above DRC in vivo (h) Figure 2 . Relationship between the time cefmenoxime serum concentrations exceeded the dynamic response concentration (DRC) for retrospectively (A) and prospectively (#) treated patients, and the days to bacterial eradication in vivo. Each data point represents one pathogen. The regression line describing the retrospective data took the form of the equation: days to eradication = 13.86-1.78 (time over dynamic response concentration), r = 0.89, P < 0.001. The dual individualized dosage method clustered the eradication day tightly around days 4 to 6. (cf. Schentag el al., 1984) . infection model, the parameter most closely associated with efficacy for erythromycin was T > MIC. For azithromycin, however, AUC correlates best with outcome, the reason being that the drug concentrates into white cells which then act as a delivery system to the site of infection (Craig, W., personal communication). For clarithromycin, both T > MIC and AUC are linked to outcome, but it is not yet possible to determine which is the more important. Thus, we can consider erythromycin in the same way as /?-lactams, azithromycin in the same way as quinolones, and clarithromycin in either scheme. However, it should be noted that the ratio of serum concentrations to MIC for quinolones can be important in terms of development of resistance. For amoxycillin and fluoroquinolones, resistant mutants can be selected if the serum level is <4 x MIC and for cephalosporins, selection occurs at < 16 x MIC. As shown in the present study, the ratio of serum level:MIC for amoxycillin against Streptococcus pneumoniae is in the range 8-1000, while for fluoroquinolones, cefaclor and cefixime the ratios range from 2 to 16. Thus, there is potential for resistance development on treatment with these agents.
Since there is no unifying scheme to compare all classes of antibiotics, how can these pharmacodynamic parameters be compared using the MIC data generated by the Alexander Project? Tables IV to VII summarise the pharmacokinetic parameters of the antibiotics tested using the recommended dosage(s), the MIC50 and MIG» against the four main pathogens and T > MIC or AUC/MIC values (as appropriate), calculated from serum/time profiles. Figures 3 to 6 show the proportion of the dose interval that /3-lactam and macrolide serum levels exceed the MIC. The following conclusions can be drawn:
Antibiotic class (i) Of the penicillins, only amoxycillin/clavulanate (at the higher dose regimen) exceeds the MIG» for the four major pathogens for > 50% of the dosing interval. Amoxycillin (higher dose) was as effective as amoxycillin/clavulanate against S. pneumoniae, but not against the other pathogens.
(ii) Of the cephalosporins, only ceftriaxone exceeds the MIQo for the four major pathogens for > 50% of the dosing interval. Cefixime was effective against Haemophilus influenzae and Moraxella catarrhalis, but none of the other oral cephalosporins exceeded the MIG» for any organism for > 50% of the dose interval.
(iii) Macrolides showed efficacy against M. cattarhalis only (at MIC™ values).
(iv) Quinolones showed the greatest potential efficacy against H. influenzae and M. catarrhalis, and the least activity against Slaphylococcus aureus and S. pneumoniae (at MIC* values). Pathogen (i) For S. pneumoniae, all /?-lactams except cefaclor had serum levels above the which is close to the MIC for normally susceptible strains, for > 50% of the dose interval. This is also true for macrolides, and to a lesser extent for ofloxacin and higher-dose ciprofloxacin.
At the MIC90, which corresponds to the modal MIC for resistant strains, only ceftriaxone and amoxycillin (± clavulanate) of the 0-lactams showed T > MIC90 exceeding 50% of the dose interval. Cefaclor, cefuroxime and cefixime are out of therapeutic range for these particular isolates. Ofloxacin had the highest AUC/MIC90 ratio.
(ii) For H. influenzae, at the MIC», ceftriaxone, cefixime and the fluoroquinolones, followed by amoxycillin (± clavulanate) have excellent activity. Cefuroxime has borderline activity, with possible usefulness against some strains. Macrolides are ineffective against these strains since serum levels are lower than MICs. At the MIG», amoxycillin is also less effective because of /Mactamase production.
(iii) For M. catarrhalis, at the MIC», amoxycillin (± clavulanate), cefixime, ceftriaxone, macrolides and fluoroquinolones are potentially effective. Cefaclor and cefuroxime may be useful against some strains. At the MICw, only cefixime, ceftriaxone and amoxycillin/clavulanate of the /Mactams, the macrolides and quinolones are likely to be effective.
(iv) For S. aureus, at the MIC50, ceftriaxone, amoxycillin/clavulanate, macrolides, fluoroquinolones, amoxycillin (higher dose) and cefuroxime (higher dose) are likely to be effective. Cefaclor may be useful against some strains, but cefixime showed poor activity. At the MIC90, only ceftriaxone and amoxycillin/clavulanate (higher dose) are likely to be effective. High dosage ciprofloxacin, ofloxacin and cefuroxime may be useful against some strains, but other /Mactams and macrolides have little to offer. 
Conclusion
How do we interpret these data? All the parameters have been calculated on the basis of the usual mean unitary dosage. For amoxycillin, because of lack of toxicity, dosages can be increased by 100%. As an example, the recommended oral dosage of amoxycillin for pneumococcal pneumonia in France is 1 g tid, compared with 500 mg tid in many other countries. This is not normally done for other oral /Mactams. Protein binding should also be considered, since this may seriously compromise the activity of some compounds, such as cefixime (protein binding = 70%) against S. pneumoniae. Selection of antibiotic should be made on the basis of the site of infection, the need for bactericidal activity and the toxicity profile, allied to a knowledge of the pharmacodynamics, for which good susceptibility data as provided by the Alexander Project are of paramount importance.
